A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.Adam Sharp, Hendrik‐Tobias Arkenau, Elizabeth Ruth Plummer et al.|Journal of Clinical Oncology|2022Cited by 12
A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including DLBCLGraham P. Collins, Dima El‐Sharkawi, Daniel Chan et al.|Blood|2023Cited by 9